KROS Keros Therapeutics Inc
Price (delayed)
$56.34
Market cap
$2.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.13
Enterprise value
$1.72B
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros
Highlights
The revenue is up by 16% since the previous quarter
The gross profit has grown by 16% from the previous quarter
KROS's equity is up by 29% year-on-year but it is down by 7% since the previous quarter
The company's net income fell by 33% YoY and by 4.8% QoQ
The quick ratio has contracted by 19% from the previous quarter and by 4.6% YoY
Key stats
What are the main financial stats of KROS
Market
Valuations
Earnings
Shares outstanding
37.52M
Market cap
$2.11B
Enterprise value
$1.72B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.83
Price to sales (P/S)
7,505.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6,350.1
Revenue
$271,000
EBIT
-$168.05M
EBITDA
-$165.65M
Free cash flow
-$146.15M
Per share
Balance sheet
Liquidity
EPS
-$5.13
Free cash flow per share
-$4.05
Book value per share
$11.66
Revenue per share
$0.01
TBVPS
$12.6
Total assets
$455.02M
Total liabilities
$34.11M
Debt
$13.96M
Equity
$420.92M
Working capital
$411.47M
Debt to equity
0.03
Current ratio
20.37
Quick ratio
19.16
Net debt/EBITDA
2.37
Margins
Efficiency
Dividend
EBITDA margin
-61,126.6%
Gross margin
100%
Net margin
-62,012.5%
Operating margin
-69,615.1%
Return on assets
-41.1%
Return on equity
-44.7%
Return on invested capital
-477.4%
Return on capital employed
-38.7%
Return on sales
-62,012.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KROS stock price
How has the Keros Therapeutics stock price performed over time
Intraday
2.9%
1 week
4.96%
1 month
25.65%
1 year
53.93%
YTD
41.7%
QTD
23.28%
Financial performance
How have Keros Therapeutics's revenue and profit performed over time
Revenue
$271,000
Gross profit
$271,000
Operating income
-$188.66M
Net income
-$168.05M
Gross margin
100%
Net margin
-62,012.5%
Keros Therapeutics's operating income has decreased by 35% YoY and by 5% from the previous quarter
The company's net income fell by 33% YoY and by 4.8% QoQ
The revenue is up by 16% since the previous quarter
The gross profit has grown by 16% from the previous quarter
Growth
What is Keros Therapeutics's growth rate over time
Valuation
What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
4.83
P/S
7,505.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6,350.1
KROS's EPS is down by 13% year-on-year
KROS's equity is up by 29% year-on-year but it is down by 7% since the previous quarter
The price to book (P/B) is 17% higher than the last 4 quarters average of 4.0
KROS's P/S is 79% below its last 4 quarters average of 35541.4
The revenue is up by 16% since the previous quarter
Efficiency
How efficient is Keros Therapeutics business performance
The ROIC has grown by 20% YoY and by 2.5% from the previous quarter
KROS's return on sales is up by 9% since the previous quarter
The ROE has contracted by 6% YoY
The company's return on assets fell by 6% YoY
Dividends
What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KROS.
Financial health
How did Keros Therapeutics financials performed over time
KROS's total assets is up by 28% YoY but it is down by 6% QoQ
The quick ratio has contracted by 19% from the previous quarter and by 4.6% YoY
The debt is 97% less than the equity
KROS's equity is up by 29% year-on-year but it is down by 7% since the previous quarter
KROS's debt to equity is down by 25% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.